Alumis is a late-stage biopharmaceutical company built around a single bet: that an oral, once-daily TYK2 inhibitor can take on a psoriasis market long dominated by injectable biologics - and do it with efficacy that, by management's telling, already sits at the top of the oral class. The second week of August answered part of that question with the strongest clinical card the company has played. Long-term data from the Phase 3 ONWARD program showed 54% of patients reached complete skin clearance (PASI 100) after 48 weeks of treatment with envudeucitinib, which the company calls the highest reported figure among oral therapies, alongside a 75% PASI 90 response. The data validate a Phase 3 program that met all primary and secondary endpoints in January, and they set the table for the operative milestone: a New Drug Application to the Food and Drug Administration for moderate-to-severe plaque psoriasis in the fourth quarter of 2026.
The financial quarter itself was unglamorous and entirely expected for a clinical-stage company without a commercial product. First-quarter revenue of $1.7 million (all collaboration service revenue from the Kaken Japan partnership, down from the $17.4 million one-time license recognition a year earlier) covered a rounding error of the $93.1 million net loss. The balance sheet, however, is the real headline asset: $569.5 million of cash, cash equivalents and marketable securities as of March 31, funded in large part by a January 2026 equity offering, which management said covers operating and capital requirements for at least the next twelve months.
At a share price of roughly $25.55, the company trades around $3.1 billion in market value - a price that embeds a successful psoriasis launch, an expanding TYK2 platform, and significant capital still to be raised for commercialization. The stock has already run roughly seven-fold off its September 2025 low of about $3.76 as the Phase 3 story came together, and it now sits about a fifth below its July 2026 high near $31. The investment case collapses into three clocks: whether the NDA lands in the fourth quarter, whether the lupus readout expected this quarter broadens the platform, and whether the ~$570 million treasury proves enough to fund a commercial build.